SLNO Soleno Therapeutics
- 46.1600
- -0.2700-0.58%
- 46.1600
- 0.00000.00%
Soleno Therapeutics News
Express News | Soleno Therapeutics Inc will soon be added to the Russell 3000 index.
Express News | Soleno Therapeutics Inc - Set to Join Russell 3000 Index
Soleno Therapeutics Set to Join Russell 3000 Index
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking.The chipmaker giant has seen an astounding 186% surge since the en
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $59
Stifel analyst Dae Gon Ha maintains $Soleno Therapeutics(SLNO.US)$ with a buy rating, and maintains the target price at $59.According to TipRanks data, the analyst has a success rate of 36.2% and a to
Piper Sandler Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $93
Piper Sandler analyst Yasmeen Rahimi maintains $Soleno Therapeutics(SLNO.US)$ with a buy rating, and maintains the target price at $93.According to TipRanks data, the analyst has a success rate of 35.
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Soleno Therapeutics (SLNO)
Soleno Therapeutics Announces Oral Presentation Featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
Soleno Therapeutics, Inc. (NASDAQ: SLNO) today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4, 2024 in Boston, Massachusetts.
Soleno Therapeutics to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
Soleno Therapeutics Stands With the Prader-Willi Syndrome Community
This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome communityREDWOOD CITY, Calif., May 15, 2024 (GLOBE N
Soleno Therapeutics Is Maintained at Outperform by Oppenheimer
Soleno Therapeutics Is Maintained at Outperform by Oppenheimer
Oppenheimer: The Soleno Therapeutics (SLNO.US) rating was maintained, and the target price was adjusted from better than the market to the better than the market rating, and the target price was adjusted from $65.00 to $59.00.
Oppenheimer: The Soleno Therapeutics (SLNO.US) rating was maintained, and the target price was adjusted from better than the market to the better than the market rating, and the target price was adjusted from $65.00 to $59.00.
Oppenheimer Maintains Outperform on Soleno Therapeutics, Lowers Price Target to $59
Oppenheimer analyst Leland Gershell maintains Soleno Therapeutics (NASDAQ:SLNO) with a Outperform and lowers the price target from $65 to $59.
Soleno Therapeutics (SLNO) Receives a Buy From Stifel Nicolaus
Soleno Therapeutics Initiated at Outperform by Baird
Soleno Therapeutics Initiated at Outperform by Baird
Soleno Therapeutics (SLNO.US) was first covered by Baird, which gave it an superior market rating, with a target price of $72.00.
Soleno Therapeutics (SLNO.US) was first covered by Baird, which gave it an superior market rating, with a target price of $72.00.
Baird Initiates Coverage On Soleno Therapeutics With Outperform Rating, Announces Price Target of $72
Baird analyst Brian Skorney initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Outperform rating and announces Price Target of $72.
Soleno Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 50.22% Baird → $72 Initiates Coverage On → Outperform 02/05/2024 94.03% Piper Sandler → $93 Ini
Soleno Therapeutics (SLNO.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.59 dollars, previous value was -0.88 dollars, and expected value was -0.37 dollars.
Soleno Therapeutics (SLNO.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.59 dollars, previous value was -0.88 dollars, and expected value was -0.37 dollars.
Soleno Therapeutics Q1 2024 Adj EPS $(0.59) Misses $(0.37) Estimate
Soleno Therapeutics (NASDAQ:SLNO) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.37) by 59.46 percent.
Analysis
Price Target
No Data
